-
SoloHealth, WellPoint provide convenience
SoloHealth recently announced a new relationship with WellPoint to help provide consumers with convenient access to information about their health and wellness through the next- generation SoloHealth Station consumer kiosks.
The news comes on the heels of SoloHealth Station’s recent Food and Drug Administration approval in June, as well as its announcement of an aggressive rollout to retail locations nationwide to begin this fall.
-
Teva launches authorized generic Actos
JERUSALEM — Teva Pharmaceutical Industries announced the launch of an authorized generic of a Type 2 diabetes drug.
The company launched pioglitazone hydrochloride tablets in the 15-mg, 30-mg and 45-mg strengths. The drug is a generic version of Takeda Pharmaceuticals' Actos.
Annual sales of Actos in the United States were approximately $2.7 billion for the 12-month period ended in June, according to IMS sales data.